DAISHOMICROLINE plans to invest CNY 28.5 million to subscribe for approximately 15.12% of the expanded registered capital of Beijing Weihang Yining Health Management Group
DAISHOMICROLINE plans to invest RMB 28.5 million to subscribe for approximately 15.12% of the registered capital of Beijing Weihang Yining Health Management Group. This investment will make the target company an associate of DAISHOMICROLINE and is expected to enhance the group's business diversification and competitiveness. The target company mainly provides health management and consulting services. After the investment is completed, the shareholding ratios of target shareholders A, B, and DAISHOMICROLINE will be 59.42%, 25.46%, and 15.12%, respectively
According to the Zhitong Finance APP, DAISHOMICROLINE (00567) announced that on March 28, 2025, the investor (an indirect wholly-owned subsidiary of the company, Guangzhou Jiasheng Electronic Trading Co., Ltd.) entered into a capital injection agreement with the target shareholders and the target company Beijing Weihang Yining Health Management Group Co., Ltd. The investor conditionally agreed to subscribe for the registered capital of the target company at a subscription price of RMB 28.5 million (equivalent to approximately HKD 30.495 million).
Upon completion, the investor will hold approximately 15.12% of the target company's expanded registered capital. Therefore, the target company will be accounted for as an associate of the company, and the financial performance of the target company will not be consolidated into the group's consolidated financial statements.
It is reported that the target group mainly engages in providing health management and health consulting services (excluding medical diagnosis and treatment activities that require approval). As of the date of this announcement and immediately before completion, the target company is owned by target shareholder A and target shareholder B, holding 70% and 30%, respectively. After completion, target shareholder A, target shareholder B, and the investor will hold approximately 59.42%, 25.46%, and 15.12% of the target company's expanded registered capital, respectively.
The board of directors believes that the capital injection will diversify the group's business scope and enhance the group's competitiveness. Since subscribing for the equity interest in the target company can diversify the group's revenue sources, the capital injection also aligns with the group's strategy to improve financial performance
